ClinicalTrials.gg
Active, not recruitingNCT07936604Updated Nov 13, 2026

Motor Control Exercise and Myofascial Release in Greater Trochanteric Pain Syndrome

An interventional study of Motor Control Exercise + Myofascial Release and Motor Control Exercise in Greater Trochanteric Pain Syndrome, sponsored by Harran University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Harran University · Not applicable, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,720 studies in Pain with a site in Turkey — 323 open to participants now, 376 under way, none of them phase 3. Pain · Turkey.

Planned enrollment
680th of 1,497
72 · median 70
Started
2026
with 183 others
No phase
1,455 of 1,720
261 open now
Primary completion
2026-11
later than 279 of 375 live
Registered
1,648th of 1,720
by date

Among the 1,720 studies in Pain with a site in Turkey, this one is the 680th largest by planned enrollment of the 1,497 interventional ones that give a count, is one of 184 that started in 2026, is one of 1,455 with no phase, reaches primary completion later than 279 of the 375 other live ones, and was the 1,648th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

323 of the 1,720 studies in Pain with a site in Turkey are open now. Recruiting first, the newest first:

318 more — sign in →

All 323 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,720 studies in Pain with a site in Turkey, or all of them as a file.
02

Study summary

Greater Trochanteric Pain Syndrome (GTPS) is a common musculoskeletal condition associated with lateral hip pain, impaired muscle function, and reduced physical performance. This randomized controlled trial aims to investigate the effects of motor control exercises combined with myofascial release techniques on pain intensity, pain threshold, muscle activation patterns, muscle strength, functional capacity, quality of life, and gait parameters in individuals diagnosed with GTPS.

A total of 72 participants with GTPS will be randomly allocated to one of three groups: (1) motor control exercises combined with myofascial release techniques, (2) motor control exercises alone, or (3) a control group receiving a home-based motor control exercise program in brochure format. Outcome measures will be assessed at baseline and after an 8-week intervention period. The results of this study may provide evidence for optimizing rehabilitation strategies for individuals with GTPS.

Read the detailed description

Greater Trochanteric Pain Syndrome (GTPS) is a clinical condition that encompasses disorders affecting the trochanteric bursa (trochanteric bursitis) and the gluteus medius and minimus tendons (gluteal tendinopathy). Individuals with GTPS commonly experience intermittent or persistent lateral hip pain around the greater trochanter, which may substantially impair daily functioning. Symptoms are often aggravated by side-lying, stair climbing, walking, transitioning from sitting to standing, and physical activity.

The primary objective of this randomized controlled trial is to evaluate the effects of motor control exercises combined with myofascial release techniques on GTPS-related symptoms, including pain intensity, pain threshold, and muscle activation patterns, as well as functional outcomes such as muscle strength, Harris Hip Score (HHS), Lower Extremity Functional Scale (LEFS), Short Form-36 (SF-36), Timed Up and Go Test (TUG), Stair Climb Test (SCT), and gait parameters.

A total of 72 participants diagnosed with GTPS will be randomly assigned to one of three groups: (1) a motor control exercise plus myofascial release group, (2) a motor control exercise group, or (3) a control group receiving a home-based motor control exercise brochure. Outcomes will be assessed at baseline and after an 8-week intervention period. The findings may contribute to the development of more effective rehabilitation strategies for individuals with GTPS.

03

Conditions studied

  • Greater Trochanteric Pain Syndrome

Browse trials for

Keywords

  • Greater Trochanteric Pain Syndrome
  • Motor Control Exercise
  • Myofascial Release
  • Hip Pain
  • Muscle Strength
  • Rehabilitation
  • Surface Electromyography
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 70 years
  • Diagnosed with Greater Trochanteric Pain Syndrome (GTPS) based on clinical examination and imaging findings
  • Presence of GTPS symptoms for at least 3 months
  • Pain intensity of ≥4 on the Numeric Pain Rating Scale (NPRS)
  • Able to read and understand Turkish
  • Willing to participate and provide written

Additional criterion for post-surgical participants:

- Diagnosed with GTPS at least 12 months after hip arthroplasty surgery

Exclusion criteria

Exclusion Criteria:

  • (BMI) >36 kg/m²
  • Neurological, cardiac, pulmonary, or orthopedic disorders limiting participation in exercise
  • Cognitive impairment, communication problems, or severe psychiatric disorders affecting compliance
  • Diagnosis of hip osteoarthritis, femoroacetabular impingement syndrome, avascular necrosis, or hip labral tear
  • Hip surgery within the previous 6 months
  • or -rich plasma (PRP) injection within the previous 3 months
  • Participation in another physiotherapy program or other treatment for GTPS within the previous 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Motor Control Exercise + Myofascial Release

    Participants will receive a motor control exercise program combined with myofascial release techniques for 8 weeks.

    Procedure: Motor Control Exercise + Myofascial Release

  • Active comparator
    Motor Control Exercise

    Participants will receive a motor control exercise program for 8 weeks.

    Procedure: Motor Control Exercise

  • Active comparator
    Home Exercise Program

    Participants will receive a home-based motor control exercise program in brochure format for 8 weeks.

    Procedure: Home Exercise Program

Interventions

  • ProcedureMotor Control Exercise + Myofascial Release

    Participants will receive a motor control exercise program combined with myofascial release techniques for 8 weeks.

  • ProcedureMotor Control Exercise

    Participants will receive a motor control exercise program for 8 weeks.

  • ProcedureHome Exercise Program

    Participants will receive a home-based motor control exercise program in brochure format for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Short-Form McGill Pain Questionnaire -Pain Rating Index

    Pain characteristics and severity will be assessed using the 15-item Pain Rating Index of the Short-Form McGill Pain Questionnaire (SF-MPQ). Each item is scored from 0 (none) to 3 (severe), resulting in a total score ranging from 0 to 45. Higher scores indicate greater pain severity and a worse outcome.

    Time frame: Baseline and 8 weeks after intervention

  2. Short-Form McGill Pain Questionnaire - Present Pain Intensity

    Current pain intensity will be assessed using the Present Pain Intensity (PPI) component of the Short-Form McGill Pain Questionnaire (SF-MPQ). Scores range from 0 (no pain) to 5 (excruciating pain), with higher scores indicating greater current pain intensity and a worse outcome.

    Time frame: Baseline and 8 weeks after intervention

  3. Short-Form McGill Pain Questionnaire - Visual Analog Scale

    Pain intensity will be assessed using the Visual Analog Scale (VAS) included in the Short-Form McGill Pain Questionnaire (SF-MPQ). The scale ranges from 0 to 10 mm, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity and a worse outcome.

    Time frame: Baseline and 8 weeks after intervention

Secondary outcomes

  1. Gluteus Medius Pressure Pain Threshold

    Pressure pain threshold of the gluteus medius muscle will be measured using a digital algometer. Measurements will be recorded in pounds-force (lbf). Three measurements will be performed, and their arithmetic mean will be calculated. Higher values indicate a higher pressure pain threshold and lower sensitivity to pressure-induced pain.

    Time frame: Baseline and 8 weeks after intervention

  2. Tensor Fasciae Latae Pressure Pain Threshold

    Pressure pain threshold of the tensor fasciae latae muscle will be measured using a digital algometer. Measurements will be recorded in pounds-force (lbf). Three measurements will be performed, and their arithmetic mean will be calculated. Higher values indicate a higher pressure pain threshold and lower sensitivity to pressure-induced pain.

    Time frame: Baseline and 8 weeks after intervention

  3. Gluteus Medius Muscle Activation During Mini Squat

    Gluteus medius muscle activation during mini squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.

    Time frame: Baseline and 8 weeks after intervention

  4. Gluteus Medius Muscle Activation During Single-Leg Squat

    Gluteus medius muscle activation during single-leg squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.

    Time frame: Baseline and 8 weeks after intervention

  5. Tensor Fasciae Latae Muscle Activation During Mini Squat

    Tensor fasciae latae muscle activation during mini squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.

    Time frame: Baseline and 8 weeks after intervention

  6. Tensor Fasciae Latae Muscle Activation During Single-Leg Squat

    Tensor fasciae latae muscle activation during single-leg squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.

    Time frame: Baseline and 8 weeks after intervention

  7. Hip Abductor Muscle Strength

    Hip abductor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip abductor muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  8. Hip Flexor Muscle Strength

    Hip flexor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip flexor muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  9. Hip Extensor Muscle Strength

    Hip extensor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip extensor muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  10. Hip Internal Rotator Muscle Strength

    Hip internal rotator muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip internal rotator muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  11. Hip External Rotator Muscle Strength

    Hip external rotator muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip external rotator muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  12. Tensor Fasciae Latae Muscle Strength

    Tensor fasciae latae muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contraction. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater muscle strength in the tested position.

    Time frame: Baseline and 8 weeks after intervention

  13. Knee Flexor Muscle Strength

    Knee flexor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater knee flexor muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  14. Knee Extensor Muscle Strength

    Knee extensor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater knee extensor muscle strength.

    Time frame: Baseline and 8 weeks after intervention

  15. Harris Hip Score

    Hip-related pain and functional status will be assessed using the Harris Hip Score. The total score ranges from 0 to 100, with higher scores indicating better hip function and less pain.

    Time frame: Baseline and 8 weeks after intervention

  16. Lower Extremity Functional Scale

    Functional limitations related to lower extremity disorders will be evaluated using Lower Extremity Functional Scale. The total score ranges from 0 to 80, with higher scores indicating better lower extremity function and fewer functional limitations.

    Time frame: Baseline and 8 weeks after intervention

  17. Short Form- 36 Physical Functioning

    Physical functioning will be assessed using the Physical Functioning domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better physical functioning.

    Time frame: Baseline and 8 weeks after intervention

  18. Short Form- 36 Role Limitations Due to Physical Health

    Role limitations due to physical health problems will be assessed using the Role Physical domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating fewer limitations due to physical health problems.

    Time frame: Baseline and 8 weeks after intervention

  19. Short Form- 36 Bodily Pain

    Bodily pain will be assessed using the Bodily Pain domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating less pain and less pain-related interference.

    Time frame: Baseline and 8 weeks after intervention

  20. Short Form- 36 General Health

    General health perceptions will be assessed using the General Health domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better perceived general health.

    Time frame: Baseline and 8 weeks after intervention

  21. Short Form- 36 Vitality

    Vitality will be assessed using the Vitality domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating greater vitality and less fatigue.

    Time frame: Baseline and 8 weeks after intervention

  22. Short Form- 36 Social Functioning

    Social functioning will be assessed using the Social Functioning domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better social functioning.

    Time frame: Baseline and 8 weeks after intervention

  23. Short Form- 36 Role Limitations Due to Emotional Problems

    Role limitations due to emotional problems will be assessed using the Role Emotional domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating fewer limitations due to emotional problems.

    Time frame: Baseline and 8 weeks after intervention

  24. Short Form- 36 Mental Health

    Mental health will be assessed using the Mental Health domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better mental health.

    Time frame: Baseline and 8 weeks after intervention

  25. Timed Up and Go Test

    Functional mobility will be assessed using the Timed Up and Go Test. The time required to stand up from a chair, walk 3 meters, turn around, walk back, and sit down will be recorded in seconds. Lower values indicate better functional mobility and performance.

    Time frame: Baseline and 8 weeks after intervention

  26. Stair Climb Test

    Functional stair-climbing performance will be assessed using the Stair Climb Test. The time required to ascend and descend a standardized flight of stairs will be recorded in seconds. Lower values indicate better stair-climbing performance and functional mobility.

    Time frame: Baseline and 8 weeks after intervention

  27. Gait Parameters- Stride Length

    Stride length will be evaluated using a powdered ground walking analysis method. The distance between two consecutive footprints of the same foot will be measured in centimeters (cm). Higher values indicate greater stride length.

    Time frame: Baseline and 8 weeks after intervention

  28. Gait Parameters-Step Width

    Step width will be evaluated using a powdered ground walking analysis method. The mediolateral distance between successive footprints will be measured in centimeters (cm). Higher values indicate greater step width.

    Time frame: Baseline and 8 weeks after intervention

  29. Gait Parameters- Cadence

    Gait cadence will be evaluated during walking using a powdered ground walking analysis method, with the number of steps and elapsed walking time recorded. Cadence will be calculated as the number of steps taken per minute (steps/min). Higher values indicate greater stepping frequency.

    Time frame: Baseline and 8 weeks after intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the study involves confidential participant health information and no data-sharing plan has been established.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.

Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 3 months is below that.

Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Nov 13, 2026
StartActual
Aug 30, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936604
Lead sponsor
Harran University
Responsible party
CANSU YILDIRIM (Lecturer, PhD Candidate, Harran University) — Principal investigator
First posted
Nov 13, 2026
Start date
Aug 30, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Serkan Usgu, Associate Professor
principal investigator · Hasan Kalyoncu University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion